Acute Myeloid Leukemia Clinical Trial
Official title:
Transplantation of Expanded and Unexpanded Umbilical Cord Blood Units Following Myeloablative Chemotherapy for Hematologic Malignancies
This study is to evaluate the safety of transplantation of two cord blood products, including toxicities in patients following high-dose, myeloablative chemotherapy for blood malignancies. It is also to determine if the use of two cord products results in an improvement in neutrophil engraftment.
The success of BMT as a curative option for patients with malignancies is frequently limited
by the inability to identify an appropriate donor in time for transplantation.
Transplantations utilizing umbilical cord blood stem cells are increasingly successful. Data
suggest that there are fewer and less developed T-cells in cord products when compared to
bone marrow and so are likely to produce less graft-vs.-host disease (GVHD) even in the
mismatched setting. In addition, the grafts are easily available second to the ease of
collection as compared with other sources such as bone marrow and peripheral blood stem cells
(PBSCs). The ability to build cord blood repositories containing samples with HLA types from
minorities has and will continue to increase the likelihood of finding suitable products for
under represented minorities such as African-Americans, Hispanic populations and mixed ethnic
populations.
Unfortunately, limitations remain, secondary to the time to engraftment when the cell dose is
less than optimal, resulting in delayed or failed engraftment. In addition, increased cell
dose appears to be associated with disease free survival. Therefore, this modality of
transplant is generally limited to smaller patients. This protocol evaluates the infusion and
engraftment of two cord blood products - one that has been expanded ex vivo and one that has
not been expanded following myeloablative chemotherapy for the treatment of hematological
malignancies.
Primary Objective:
-To evaluate the safety of transplantation of two cord products including an expanded unit
including infusional toxicities and potential immunologic competition.
Secondary Objective:
-To determine if the use of two cord products results in an improvement in neutrophil
engraftment (ANC>500) in subjects as demonstrated by engraftment <=21 days.
Tertiary Objectives:
Patients will be compared with patients participating in other trials at our institution and
to those who receive therapy as per standard of care.
- To evaluate the rate, extent, and durability of hematopoietic reconstitution and in
particular to determine the relative contribution of each cord unit in early engraftment
and long-term engraftment
- To estimate the rate and severity of graft-vs-host disease
- To estimate the rates of infectious complications
- To obtain preliminary data regarding disease-free and overall survival
- To collect samples for future studies of immune reconstitution and for future studies in
the laboratory regarding disease and the immune system
We will be able to track the fate of both the unmanipulated and expanded CB progenitors by
evaluating differences in the cord products and the recipient by evaluation of sex mismatch,
HLA type and/or restriction length polymorphisms (RFLPs). If the expanded CB cells are
detected in the patients long-term, this will give us confidence to use expanded CB as the
sole hematopoietic progenitor cell support, in future studies.
The major risk is non-engraftment of either one or both of the cord blood units.
Non-engraftment of one of the units may lead to prolonged cytopenia and a marked increased
risk for infection. Failure of either unit to engraft as defined as failure to detect cells
from either cord blood product at Day +60 is likely to result in the death of the subject.
There is the possibility of failure of long-term engraftment from both cords. This would be
fatal unless an alternative donor option was identified or the unlikely event of autologous
reconstitution of bone marrow. There is a possibility of an immune competition of both cord
blood products . This could result in the loss of the cord product that would have been
responsible for long term engraftment. There is a possibility of the expanded cord product to
fail release testing. In this event, only the unexpanded cord would be infused and would
likely result in delayed engraftment.
As with all cellular products there are risks associated with the infusion including but not
limited to anaphylaxis, transfusion reaction, hemolysis, side-effects of the DMSO that the
product is stored in (bradycardia, hypothermia, neurologic changes). The expanded product
will be washed however there remains a small chance that a small amount of growth factor
remains. The risk associated with these will be allergic.
Busulfan toxicity
1. Nausea and vomiting
2. Myeloablation
3. Pulmonary complications
4. Seizures
5. Other toxic effects which may be produced by Busulfan erythematous skin rash,
hyperpigmentation, hepatic dysfunction, amenorrhea, testicular atrophy, gynecomastia,
myasthenia symptoms, cataract and atrophic bronchitis associated with cytologic
dysplasia.
Cyclophosphamide Toxicity
1. Leukopenia, anemia
2. Alopecia
3. Nausea, vomiting, increased AST, ALT, mucositis, diarrhea
4. Headache, dizziness
5. Cardiac necrosis rarely with high dose cyclophosphamide
6. Hemorrhagic cystitis, SIADH
7. Teratogenic, may cause secondary neoplasms, anaphylaxis (rare)
8. Fluid retention.
9. Cardiomyopathy.
10. Hemorrhagic Cystitis.
At the doses used for uroprotection mesna is virtually non-toxic. However, adverse effects
which may be attributable to mesna include nausea and vomiting, diarrhea, abdominal pain,
altered taste, rash, urticaria, headache, joint or limb pain, hypotension and fatigue.
Total Body Irradiation Toxicity:
1. Nausea and Vomiting
2. Alopecia
3. Parotitis and Pancreatitis
4. Diarrhea
5. Fever
6. Erythema
7. Hyperpigmentation
8. Mucositis
9. Late Effects - cataract formation, growth retardation, carcinogenesis and the
probability of sterilization.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Recruiting |
NCT04460235 -
Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma
|
Phase 4 | |
Completed |
NCT03678493 -
A Study of FMT in Patients With AML Allo HSCT in Recipients
|
Phase 2 | |
Completed |
NCT04022785 -
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
Recruiting |
NCT05424562 -
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
|
||
Terminated |
NCT03224819 -
Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)
|
Early Phase 1 | |
Completed |
NCT03197714 -
Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia
|
Phase 1 | |
Active, not recruiting |
NCT04070768 -
Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Active, not recruiting |
NCT04107727 -
Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)
|
Phase 2 | |
Recruiting |
NCT04385290 -
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04920500 -
Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients
|
N/A | |
Recruiting |
NCT03897127 -
Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
|
Phase 3 | |
Active, not recruiting |
NCT04021368 -
RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
|
Phase 1 | |
Recruiting |
NCT03665480 -
The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML
|
Phase 2/Phase 3 | |
Completed |
NCT02485535 -
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
|
Phase 1 | |
Enrolling by invitation |
NCT04093570 -
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers
|
Phase 2 | |
Recruiting |
NCT04069208 -
IA14 Induction in Young Acute Myeloid Leukemia
|
Phase 2 | |
Recruiting |
NCT05744739 -
Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)
|
Phase 1 | |
Recruiting |
NCT04969601 -
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
|
Phase 1/Phase 2 |